This examined current techniques and applications, customers' plans for using DNA microarray over the next three years, as well as preferred products, purchasing and new developments. The findings of this study provide valuable support to developers and vendors operating in this field.

This study involved the participation of more than 200 experienced DNA microarray users and decision-makers in 37 countries. It investigated DNA microarray methods, companies and products, their strengths and weaknesses, current and future annual budgets, budget breakdown, consumables, challenges, innovation, biomarkers, bioinformatics software, sample preparation, quality control guidelines and other areas. As part of this study, DNA microarray customers provided details of their anticipated purchases from suppliers in this field, over the period 2012 - 2015.

Key Report Features

1) Routine use: Use of DNA microarrays by end-users for running routine (developed and validated) microarray tests, the development or validation of microarray tests and for the qualitative discovery using microarray methods

2) Companies: Purchases of DNA microarrays and related systems by end-users from more than 30 companies and anticipated DNA microarray purchases by end-users from more than 30 companies over the next three years, each ranked according to their competitive position.

3) Microarray Methods: Current use of more than 15 DNA microarray methods by end-users and the anticipated use of these methods by end-users over the next three years, each ranked according to their competitive position.

4) Microarray Application: Current use of more than 20 DNA microarray applications by end-users and the anticipated use of these applications by end-users over the next three years, each ranked according to their competitive position.

5) Preferred Companies: End-users' preferred companies in the DNA microarray field, each ranked according to their competitive position.

6) Products: End-users' preferred products (and associated companies) in the DNA microarray field, each ranked according to their competitive position.

7) Strengths: End-users' disclosures of the strengths of their preferred products in the DNA microarray field, each ranked according to their competitive position.

8) Weaknesses: End-users' disclosures of the weaknesses of their preferred products in the DNA microarray field, each ranked according to their relative position.

9) Current Financial Budgets: End-users' annual financial budgets for DNA microarray studies.

10) Current Budget Breakdown: The breakdown of end-users' DNA microarray financial budgets in eight key areas, relating to their current expenditure on DNA microarray products and activities.

11) Future Budget Breakdown: The breakdown of end-users' microarray financial budgets in eight key areas, relating to their anticipated expenditure over the next three years, on DNA microarray products and activities.

12) Future Financial Budgets: End-users' anticipated changes (percentage increases or decrease) over the next three years, relating to their DNA microarray activities

13) Consumables: End-users' top three consumables, associated with their DNA microarray activities.

14) Quality Control Guidelines: End-users' adherence to established quality control guidelines or procedures (e.g. MAIME), relating to the conduct of DNA microarray studies.

15) Current Challenges: End-users' disclosures on molecular types that present the greatest technical challenges to DNA microarray analysis, together with the associated sample types (matrices), associated microarray methods and underlying reasons.

16) Innovation: End-users' current needs relating to 12 key areas of required innovation in the DNA microarray field, each ranked (on a scale of 1 to 10) according to their importance.

17) Recent Innovations: End-users disclosures on the most important innovations relating to their use of DNA microarrays, over the last three years.

18) Future Innovation: End-users' disclosures on what they anticipate will be the most important innovations in the DNA microarray field, over the next three years.

19) Biomarkers: End-users' application of DNA microarray methods for the study of disease biomarkers, including molecular types and their clinical utilities.

20) Organisations: End-users organisations include clinics or hospitals, government bodies, large international companies, research institutes, small and medium sized companies, universities and veterinary centres.

21) Fields: End-users underlying fields include biotechnology, chemicals, clinical or hospital, defence, energy, environmental, food and drink, forensics, geology, government, healthcare, natural products, pharmaceuticals, research institutes, security and universities.

22) Bioinformatics Software: End-users' disclosures on their preferred bioinformatics software, associated with DNA microarray studies.

23) Purpose: End-users' underlying reasons for using DNA microarray analysis across 13 major fields (biotechnology, chemicals, clinical or hospital, defence, energy, environmental, food and drink, forensics, geology, government, healthcare, natural products, pharmaceuticals, research institutes, security, university), each ranked according to their relative importance.

24) Study Samples: Study sample types analysed by end-users using DNA microarray methods, each ranked according to their relative importance.

25) Sample Preparation: The use of sample preparation methods by end-users for DNA microarray studies, each ranked according to their importance.

Click for Report details:DNA Microarray 2012: Market Needs, Emerging Developments and Future Use